JP7191087B2 - 血清中半減期の増強のための操作された抗体ｆｃバリアント - Google Patents

血清中半減期の増強のための操作された抗体ｆｃバリアント Download PDF

Info

Publication number
JP7191087B2
JP7191087B2 JP2020507074A JP2020507074A JP7191087B2 JP 7191087 B2 JP7191087 B2 JP 7191087B2 JP 2020507074 A JP2020507074 A JP 2020507074A JP 2020507074 A JP2020507074 A JP 2020507074A JP 7191087 B2 JP7191087 B2 JP 7191087B2
Authority
JP
Japan
Prior art keywords
polypeptide
domain
binding
antibody
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020507074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530296A5 (enExample
JP2020530296A (ja
Inventor
ジョージ ジョルジオ，
チャン－ハン リー，
テ ヒュン カン，
Original Assignee
リサーチ ディベロップメント ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ ディベロップメント ファウンデーション filed Critical リサーチ ディベロップメント ファウンデーション
Publication of JP2020530296A publication Critical patent/JP2020530296A/ja
Publication of JP2020530296A5 publication Critical patent/JP2020530296A5/ja
Priority to JP2022126967A priority Critical patent/JP7583767B2/ja
Application granted granted Critical
Publication of JP7191087B2 publication Critical patent/JP7191087B2/ja
Priority to JP2024193182A priority patent/JP2025013474A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020507074A 2017-08-11 2018-08-11 血清中半減期の増強のための操作された抗体ｆｃバリアント Active JP7191087B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022126967A JP7583767B2 (ja) 2017-08-11 2022-08-09 血清中半減期の増強のための操作された抗体ｆｃバリアント
JP2024193182A JP2025013474A (ja) 2017-08-11 2024-11-01 血清中半減期の増強のための操作された抗体ｆｃバリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544622P 2017-08-11 2017-08-11
US62/544,622 2017-08-11
PCT/US2018/046398 WO2019033087A1 (en) 2017-08-11 2018-08-11 MODIFIED FC ANTIBODY VARIANTS FOR ENHANCED SERIAL HALF LIFE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022126967A Division JP7583767B2 (ja) 2017-08-11 2022-08-09 血清中半減期の増強のための操作された抗体ｆｃバリアント

Publications (3)

Publication Number Publication Date
JP2020530296A JP2020530296A (ja) 2020-10-22
JP2020530296A5 JP2020530296A5 (enExample) 2021-10-21
JP7191087B2 true JP7191087B2 (ja) 2022-12-16

Family

ID=65272701

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020507074A Active JP7191087B2 (ja) 2017-08-11 2018-08-11 血清中半減期の増強のための操作された抗体ｆｃバリアント
JP2022126967A Active JP7583767B2 (ja) 2017-08-11 2022-08-09 血清中半減期の増強のための操作された抗体ｆｃバリアント
JP2024193182A Pending JP2025013474A (ja) 2017-08-11 2024-11-01 血清中半減期の増強のための操作された抗体ｆｃバリアント

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022126967A Active JP7583767B2 (ja) 2017-08-11 2022-08-09 血清中半減期の増強のための操作された抗体ｆｃバリアント
JP2024193182A Pending JP2025013474A (ja) 2017-08-11 2024-11-01 血清中半減期の増強のための操作された抗体ｆｃバリアント

Country Status (9)

Country Link
US (3) US11059892B2 (enExample)
EP (1) EP3665195A4 (enExample)
JP (3) JP7191087B2 (enExample)
KR (1) KR102867311B1 (enExample)
CN (1) CN111032688A (enExample)
AU (1) AU2018314257B2 (enExample)
CA (1) CA3072099A1 (enExample)
IL (1) IL272561A (enExample)
WO (1) WO2019033087A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599389A (zh) * 2019-08-22 2022-06-07 奇达拉治疗公司 变体fc结构域及其用途
EP4225787A4 (en) * 2020-05-21 2024-10-23 Zydus Lifesciences Limited FC VARIANT AND PRODUCTION THEREOF
PT4244396T (pt) * 2020-11-11 2025-10-20 Gilead Sciences Inc Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CN117203238A (zh) 2021-04-23 2023-12-08 普方生物制药美国公司 Cd70结合剂、其偶联物及其使用方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20250188186A1 (en) * 2021-12-10 2025-06-12 Board Of Regents, The University Of Texas System Ph-selective antibody fc domains
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
CA3265134A1 (en) 2022-08-26 2024-02-29 Gilead Sciences Inc DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
AU2024275646A1 (en) 2023-05-24 2025-11-13 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025117639A1 (en) 2023-11-27 2025-06-05 Profoundbio Us Co. Antibodies and methods for ptk7 detection
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025171006A1 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2014528906A (ja) 2011-09-30 2014-10-30 中外製薬株式会社 抗原クリアランスを促進するＦｃＲｎ結合ドメインを有する治療用抗原結合分子
JP2015226477A (ja) 2014-05-30 2015-12-17 トヨタ自動車株式会社 組換え微生物及び当該組換え微生物を用いた物質製造方法
WO2016071376A2 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
JP2019033743A (ja) 2017-08-03 2019-03-07 アムジエン・インコーポレーテツド インターロイキン−２１ムテイン及び治療方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7094571B2 (en) 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7419783B2 (en) 2001-11-05 2008-09-02 Research Development Foundation Engineering of leader peptides for the secretion of recombinant proteins in bacteria
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20030219870A1 (en) 2002-03-23 2003-11-27 George Georgiou Secretion of proteins with multiple disulfide bonds in bacteria and uses thereof
US7611866B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Selection of bacterial inner-membrane anchor polypeptides
US9051373B2 (en) * 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006076594A2 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
DK2134847T3 (en) 2007-03-07 2015-10-05 Univ Aarhus Pig Model for atherosclerosis
EP2155789B1 (en) 2007-05-01 2013-07-24 Research Development Foundation Immunoglobulin fc libraries
JP5683581B2 (ja) 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CN104010659A (zh) * 2011-12-19 2014-08-27 洛克菲勒大学 非唾液酸化的抗炎多肽
DK2857419T3 (da) * 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
WO2015175874A2 (en) * 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2014528906A (ja) 2011-09-30 2014-10-30 中外製薬株式会社 抗原クリアランスを促進するＦｃＲｎ結合ドメインを有する治療用抗原結合分子
JP2015226477A (ja) 2014-05-30 2015-12-17 トヨタ自動車株式会社 組換え微生物及び当該組換え微生物を用いた物質製造方法
WO2016071376A2 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
JP2019033743A (ja) 2017-08-03 2019-03-07 アムジエン・インコーポレーテツド インターロイキン−２１ムテイン及び治療方法

Also Published As

Publication number Publication date
US20190048078A1 (en) 2019-02-14
IL272561A (en) 2020-03-31
AU2018314257B2 (en) 2025-03-27
CN111032688A (zh) 2020-04-17
WO2019033087A1 (en) 2019-02-14
EP3665195A4 (en) 2021-05-19
AU2018314257A1 (en) 2020-02-13
CA3072099A1 (en) 2019-02-14
JP2025013474A (ja) 2025-01-24
JP2022145845A (ja) 2022-10-04
JP7583767B2 (ja) 2024-11-14
KR20200035972A (ko) 2020-04-06
US20210347891A1 (en) 2021-11-11
EP3665195A1 (en) 2020-06-17
US20240270852A1 (en) 2024-08-15
US11958904B2 (en) 2024-04-16
JP2020530296A (ja) 2020-10-22
KR102867311B1 (ko) 2025-10-01
US11059892B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
JP7583767B2 (ja) 血清中半減期の増強のための操作された抗体ｆｃバリアント
JP7082484B2 (ja) ポリペプチド異種多量体の製造方法
CN110894240B (zh) 结合cd3和肿瘤抗原的异二聚体抗体
TWI700292B (zh) 多胜肽異種多聚體之製造方法
JP6724023B2 (ja) 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
US10526408B2 (en) Engineered antibody FC variants
CN108025046A (zh) 结合cd3和肿瘤抗原的异二聚体抗体
WO2012170072A1 (en) Engineered antibody-tnfsf member ligand fusion molecules
JP7774447B2 (ja) 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
TW202325734A (zh) 抗cd3抗體
KR20250112243A (ko) Ph-의존성 항-cd3 항체 및 이와 관련된 방법
JP2025519556A (ja) 操作されたＦｃＲＩＩｂ選択的ＩｇＧ１ Ｆｃバリアントおよびその使用
RU2831840C2 (ru) Высокоаффинные антитела к cd3 и способы их получения и применения
US20240209096A1 (en) Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2023201966A1 (zh) 一种包含IgG类Fc区变体的抗体及其用途
WO2025169945A1 (ja) 安定性が改善されたｃｄ３標的抗原結合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221206

R150 Certificate of patent or registration of utility model

Ref document number: 7191087

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250